Alex Brill, CEO of Matrix Global Advisors, gave a presentation during the GRx+Biosims 2018 conference in Baltimore, Maryland that discussed the barriers to increased uptake of biosimilars in the United States, and how to address those issues.
Alex Brill, CEO of Matrix Global Advisors, gave a presentation during the GRx+Biosims 2018 conference in Baltimore, Maryland that discussed the barriers to increased uptake of biosimilars in the United States, and how to address those issues.
As Brill sees it, there are 4 main categories of barriers to biosimilar uptake: reference product manufacturers, biosimilar manufacturers, policy, and education.
In terms of reference product manufactures, Brill noted that drug developers have put up hurdles to biosimilar uptake in the form of their rebate practices. “Certain reference product manufacturers have conducted aggressive strategies with payers where if a payer were to put a biosimilar on its formulary, it would lose the rebate discount provided by the reference product,” said Brill.
Read more about exclusionary contracting.
The solution, he says, comes down to which stakeholder group is being addressed. For payers, he recommends adopting a longer-term perspective when negotiating contracts and designing formularies. For employers, he said the key is to identify cost-saving opportunities for their businesses as well as for their patients. Finally, for drug makers, he said that manufacturers need to ensure fair market access for biosimilars.
Certain barriers to uptake are also “natural” as Brill puts it, such as market uncertainty for consumers and biosimilar manufacturers alike. “These products are expensive and take time to develop. There’s also a lot of uncertainty with regard to other competitors…how many other people are pursuing access to the same market for the same reference product?”
In addition, biosimilars have seen relatively limited market share thus far, which could potentially be due to discounts not being sufficient. To address these challenges, payers should institute policies to drive greater biosimilar utilization, and likewise, manufacturers need to be able to offer competitive contracting terms.
As far as policy is concerned, Brill believes the United States is moving in the right direction. The recent changes on the payment front from CMS were positive steps, but there remains more to do. “There’s an opportunity right now for relevant agencies to reevaluate the market and make sure that there are not unnecessary barriers that they’re imposing on this market,” he said.
Challenges such as the “patent thickets” that have been created, wherein a reference product developer looks to protect itself from competition by registering more patents, is something that law makers will need to address and hopefully do away with, according to Brill.
Finally, one of the biggest challenges to biosimilar uptake is the lack of stakeholder education and awareness. There is currently very limited prescribing experience, and healthcare providers have largely remained hesitant when it comes to prescribing these products to patients. Education should be provided not only to the patient and to the physician, but to the payers as well so that every stakeholder understands the what the product is, how it works, and how it should be paid for.
“No one challenge is any worse than another, but it needs a holistic approach of working across these barriers. Patient groups, industry, physician groups, and the FDA itself can play an important role in educating and informing the market,” said Brill.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.